PCSK9 and myocardial infarction: At present, additional on-going large-sized multicenter randomized studies were not included in our study, such as the Phase III FOURIER, GLAGOV and GAUSS-3 trial41–43, which are intended to determine if PCSK9-mAbs can help to not only reduce LDL-C level obviously, but also improve cardiovascular related events such as myocardial infarction(MI), and the rates of morbidity and mortality.